At the 2006 Berkshire Hathaway (BRK.A)(BRK.B) Annual Meeting, a shareholder asked Warren and Charlie to dive deeper into their thoughts on an individual�� circle of competence; here is what they had to say (with emphasis added):
Warren: ��e are best at evaluating businesses where we can come to a judgment that they will look a lot like they do now in five years. The businesses will change, but the fundamentals won��. Iscar will be better ��maybe a lot bigger ��in five years, but the fundamentals will be the same��/p>
Charlie says we have three boxes: ��n,����ut��and ��oo hard.��You don�� have to do everything well. At the Olympics, if you run the 100 meters well, you don�� have to do the shot put��/p>
Tom Watson [the founder of IBM] said, ���� no genius. I�� smart in spots and I stay around those spots.��We have a lot of managers who are the same. You don�� want to compete with Pete Liegl [the CEO of Forest River; Warren made an offer for the company in 2005 one day after learning about it] because he��l kill you in the RV business. But he doesn�� try to tell us how to run the insurance business���
Best Supermarket Stocks To Invest In 2015: Gevo Inc (GEVO)
Gevo, Inc., incorporated in June 2005, is a renewable chemicals and advanced biofuels company. The Company is focused on the development and commercialization of alternatives to petroleum-based products. The Company operates in two segments: Gevo, Inc. Segment and Gevo Development/Agri-Energy Segment. Gevo, Inc. Segment is responsible for all research and development activities related to the future production of isobutanol, maintaining and protecting its intellectual property portfolio, developing future markets for its isobutanol and providing corporate oversight services. Its Gevo Development/Agri-Energy Segment is responsible for the production of ethanol and related products. In September 2010, the Company acquired a 22 MGPY ethanol production facility in Luverne, Minnesota that the Company intends to retrofit to produce isobutanol.
The Company�� isobutanol can also be converted by its customers into a range of hydrocarbons, which form the basis for the production of many products, including plastics, fibers, rubber and other polymers and hydrocarbon fuels, including jet and diesel fuel. Its technology platform consists of biocatalysts and a isobutanol separation unit. Together these technologies form the Gevo Integrated Fermentation Technology (GIFT). GIFT is designed to allow relatively low capital expenditure retrofits of existing ethanol facilities, enabling isobutanol production from a range of renewable feedstocks. The Company�� biocatalysts are microorganisms that have been designed to metabolize sugars to produce isobutanol.
GIFT consists of two components, biocatalysts which convert sugars derived from multiple renewable feedstocks into isobutanol through fermentation, and a separation unit which is designed to continuously separate isobutanol from water during the fermentation process. The Company developed its technology platform to be compatible with the existing approximately 20 BGPY of global operating ethanol production capacity, as estimated by the R! enewable Fuels Association (RFA).
The Company competes with Butamax Advanced Biofuels LLC (Butamax), BP p.l.c. (BP), E. I. du Pont de Nemours and Company, Butalco GmbH, Cathay Industrial Biotech Ltd., METabolic EXplorer S.A., TetraVitae Bioscience, Inc., Cobalt Technologies, Inc., Green Biologics Ltd. Shell Oil Products US (Shell Oil), BP, DuPont-Danisco Cellulosic Ethanol LLC, Abengoa Bioenergy, S.A., POET, LLC, ICM, Mascoma, Range Fuels, Inbicon A/S, INEOS New Planet BioEnergy LLC, Coskata, Archer Daniels Midland Company, BlueFire Ethanol, Inc., KL Energy Corporation, ZeaChem Inc., Iogen Corporation, Qteros, Inc., and AE Biofuels, Inc.
Advisors' Opinion:- [By Maxx Chatsko]
The real news came this morning, when�Gevo (NASDAQ: GEVO ) �announced that it had resumed commercial production of isobutanol at its Luverne biorefinery. The company had outlined its plans in prior conference calls, and its guidance earlier this year. But, given contamination obstacles at Luverne last summer, I suppose investors have reserved the right to remain cautious. Now that commercial production of isobutanol is finally happening, what exactly does this mean for investors?
Top 5 Healthcare Equipment Companies To Watch For 2014: AMAG Pharmaceuticals Inc.(AMAG)
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). Its principal product includes Feraheme (ferumoxytol) injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company is pursuing marketing applications in the European Union, Canada, and Switzerland for Feraheme for the treatment of IDA in CKD patients. AMAG Pharmaceuticals was founded in 1981 and is based in Lexington, Massachusetts.
Advisors' Opinion:- [By John Udovich]
The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:
- [By Monica Gerson]
AMAG Pharmaceuticals (NASDAQ: AMAG) shares fell 16% to $18.38 in the pre-market trading after the company received a CRL from the FDA for the supplemental NDA for Feraheme for broader IDA indication.
Top 5 Healthcare Equipment Companies To Watch For 2014: Neuralstem Inc (CUR)
Neuralstem, Inc., incorporated in 1997, is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form base for its research and development efforts in the area of neural stem cell research. The Company's focus is the development of methods to generate replacement cells from neural stem cells.
In October of 2011, the Company announced that after reviewing safety data from the first 12 patients, the FDA granted approval for the trial to advance to transplanting patients in the cervical (upper back) region for the last six patients in the trial. As of December 31, 2011, the Company had treated 14 patients. In February of 2011, the Company commenced a Phase Ia clinical trial of its drug compound, NSI-189, which is being developed for the treatment of depressive disorder and other psychiatric indications. In October of 2011, the Company completed the Phase Ia portion of the trial. In December of 2011, the Company received approval from the FDA to commence the Phase Ib portion of the trial.
During the year ended December 31, 2011, the Company was selected as the primary subcontractor for the United States Department of Defense (DOD) contract to develop human neural stem cell technology for the treatment of cancerous brain tumors. The Company commenced work on the project in May 2011. The Company has developed and patented a series of small molecule compounds (low molecular weights organic compounds which can efficiently cross the blood/brain barrier).
Advisors' Opinion:- [By James E. Brumley]
Nine times out of ten, I'd be hesitant to be bullish on a stock that's already made a 57% run up in just five months. Neuralstem, Inc. (NYSEMKT:CUR) is that one out of ten instances though, where there's plenty more room ahead to keep on running. In fact, I think CUR could almost double in value from where it is now before the rally effort ran out of gas.
- [By GuruFocus]
George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated
- [By John Udovich]
The results of a recent Pew Center Poll regarding attitudes towards abortion and various forms of stem cell research could be a good sign for the stem cell industry along with small cap stem cell stocks like StemCells Inc (NASDAQ: STEM), NeoStem Inc (NASDAQ: NBS), Neuralstem, Inc (NYSEMKT: CUR),�International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX). Basically, Americans think that having an abortion is a moral issue with 49% of American adults believing abortion is morally wrong, 23%�view it not as a moral issue and and 15% view it as morally acceptable. However and when Americans were asked about issues surrounding�human embryos, such as stem cell research or in vitro fertilization, as a matter of morality, their views were different.
- [By Roberto Pedone]
Neuralstem (CUR) is a biotechnology company, which is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. This stock closed up 6.1% to $1.72 in Thursday's trading session.
Thursday's Range: $1.59-$1.72
52-Week Range: $0.49-$1.96
Thursday's Volume: 590,000
Three-Month Average Volume: 474,694From a technical perspective, CUR ripped higher here right above its 50-day moving average of $1.57 with above-average volume. This move is quickly pushing shares of CUR within range of triggering a major breakout trade above a former double top area. That trade will hit if CUR manages to take out some near-term overhead resistance levels at $1.75 to $1.79 with high volume.
Traders should now look for long-biased trades in CUR as long as it's trending above its 50-day at $1.57 or above more key support levels at $1.55 to $1.43 and then once it sustains a move or close above those breakout levels with volume that hits near or above 474,694 shares. If that breakout hits soon, then CUR will set up to re-test or possibly take out its 52-week high at $1.96. Any high-volume move above that level will then give CUR a chance to tag $2.20 to $2.50.
Top 5 Healthcare Equipment Companies To Watch For 2014: Fifth Third Bancorp (FFH)
Fifth Third Bancorp (the Bancorp), incorporated on October 7, 1974, is a diversified financial services company. As of December 31, 2011, the Bancorp had $117 billion in assets, operated 15 affiliates with 1,316 full-service Banking Centers, including 104 Bank Mart locations open seven days a week inside select grocery stores, and 2,425 automated teller machines (ATMs) in 12 states throughout the Midwestern and Southeastern regions of the United States. The Bancorp operates in four business segments: Commercial Banking, Branch Banking, Consumer Lending and Investment Advisors. The Bancorp also has a 49% interest in Vantiv Holding, LLC.
Commercial Banking
Commercial Banking offers credit intermediation, cash management and financial services to large and middle-market businesses and government and professional customers. In addition to the traditional lending and depository offerings, Commercial Banking products and services include global cash management, foreign exchange and international trade finance, derivatives and capital markets services, asset-based lending, real estate finance, public finance, commercial leasing and syndicated finance.
Branch Banking
Branch Banking provides a range of deposit and loan and lease products to individuals and small businesses through 1,316 full-service Banking Centers. Branch Banking offers depository and loan products, such as checking and savings accounts, home equity loans and lines of credit, credit cards and loans for automobiles and other personal financing needs, as well as products designed to meet the specific needs of small businesses, including cash management services.
Consumer Lending
Consumer Lending includes the Bancorp�� mortgage, home equity, automobile and other indirect lending activities. Mortgage and home equity lending activities include the origination, retention and servicing of mortgage and home equity loans or lines of credit, sales and securitizations of t! hose loans, pools of loans or lines of credit, and all associated hedging activities. Indirect lending activities include loans to consumers through mortgage brokers and automobile dealers.
Investment Advisors
Investment Advisors provides a range of investment alternatives for individuals, companies and not-for-profit organizations. Investment Advisors is made up of four main businesses: Fifth Third Securities (FTS), an indirect wholly owned subsidiary of the Bancorp; Fifth Third Asset Management, Inc. (FTAM), an indirect wholly owned subsidiary of the Bancorp; Fifth Third Private Bank; and Fifth Third Institutional Services. FTS offers full service retail brokerage services to individual clients and broker dealer services to the institutional marketplace. FTAM provides asset management services and also advises the Bancorp�� family of mutual funds. Fifth Third Private Bank offers holistic strategies to affluent clients in wealth planning, investing, insurance and wealth protection. Fifth Third Institutional Services provide advisory services for institutional clients including states and municipalities.
Advisors' Opinion:- [By Bloomberg]
Mattel (MAT), the world's largest toymaker, agreed to buy Mega Brands (MB) for $460 million, acquiring the biggest challenger to Lego A/S in the construction-toy market. Mattel is offering C$17.75 ($16) a share, according to a statement today, a 36 percent premium over yesterday's closing price. The board of Montreal-based Mega Brands unanimously approved the transaction, and investors holding 39 percent of the stock, including Chief Executive Officer Marc Bertrand and Fairfax Financial Holdings (FFH), agreed to the deal. The purchase of Mega Brands, the world's second-largest maker of snap-together blocks, will fill a product hole for Mattel. It doesn't have its own construction line, locking it out of a $4 billion market in the U.S. and Europe. The category also is a bright spot in a toy industry that has seen growth stall in the U.S. Mattel considered starting its own construction line, then opted instead to buy Mega Brands because it would be faster and less risky, Mattel CEO Bryan G. Stockton said on a call with reporters. Mattel got its first taste of construction in 2012 when it debuted blocks for its Barbie brand through a licensing deal with Mega Brands. Mattel realized that replicating this kind of expertise would take years, Stockton said. 'About Growth' "This acquisition is all about growth," Stockton said. "We see an opportunity to expand our brands in this category across boys, girls and preschool." Mattel shares rose 0.8 percent to $37.44 at 10:34 a.m. in New York. They had declined 9 percent over the past year through yesterday. Shares of Montreal-based Mega Brands surged 36 percent to C$17.73 today in Toronto. Mattel is coming off a lackluster holiday season, with sales sinking 6.3 percent -- the biggest quarterly drop since 2009. The El Segundo, California-based toymaker has looked to acquisitions to boost sales in the past. In February of 2012, it paid $680 million to buy HIT Entertainment, owner of Thomas the Tank Engine. It also acq
- [By Riddhi Kharkia]
Last year, Blackberry investors were not quite pleased with the collapse of a $4.7 billion buyout by Fairfax Financial Holdings Ltd. (FFH) because the management had clearly highlighted the vulnerable cash position of the company and an uncontrollable rate of cash burn that reduced the time available to the company to bounce back. However, in retrospect, the decision made by FairFax to abandon the deal and instead fund the company with $1 billion in convertible bonds along with the appointment of a new management team proved to be beneficial for the struggling giant. In a bid to create superior products and innovate on the existing products, the current management has sparked reasonable hope among investors of a possible comeback.
No comments:
Post a Comment